asd

Aptamer Group shares jump on revenue growth and strong order book

Aptamer Group plc, the AIM-listed developer of Optimer® binders for life sciences innovation, has revealed a significant upturn in sales in its trading update for the year ending 30 June 2024.

The company reported unaudited revenue of approximately £0.85 million, with £0.55 million generated in the second half of the year, suggesting gathering momentum for the company.

- Advertisement -

Aptamer Group shares were 5.50% higher at the time of writing.

The company’s order book has shown promising growth, with £0.98 million in orders won in the final quarter alone. This surge has resulted in a total of £1.8 million in signed orders currently being processed or awaiting processing in the laboratory.

Investors will also be encouraged by a pipeline of advanced sales negotiations totalling £2.1 million.

On the technical front, Aptamer Group has made substantial progress in advancing key Optimer assets. The company is working with a top-five pharmaceutical company to evaluate Optimer binders for Immunohistochemistry (IHC), with potential for licensing. In partnership with Neuro-Bio, Aptamer is developing a rapid diagnostic test for early Alzheimer’s disease, with negotiations for downstream royalties underway.

- Advertisement -

The company has also submitted a patent application for Optimer binders intended for the treatment of malodour, with on-person functionality studies planned for the second half of 2024. This project, if successful, could result in licensing the Optimer binders to Unilever.

“The trajectory of both sales and revenue shows increasing potential, putting Aptamer Group on a good footing for the forthcoming year.,” said Steve Hull, Executive Chair of Aptamer Group

“The team has worked hard to rebuild the pipeline in the past year, and it is pleasing to see we have achieved a continued increase in sales throughout the year, with £0.98 million sales orders signed in the final quarter alone showing this work is beginning to pay off for the Company.

“We have made excellent technical progress this year having focussed on key strategic assets. Successful work is ongoing with Unilever to deliver Optimers aimed for use in personal care products, and we have had high interest from multiple top pharma companies in our Optimer delivery vehicles for fibrotic liver disease. As we continue to progress these projects with our partners, the Company increases its potential to generate significant licensing revenue from these high-value assets.”

Latest News

Subscribe to the UK Investor Magazine email newsletter

Register for our free email newsletter and receive the latest investment news, podcasts, event information and offers.

More Articles Like This

Tagdiv Cloud library - template content.